Pharmacyte Biotech, Inc. (PMCB): Modelo de negócios Canvas [Jan-2025 Atualizado]

No mundo da biotecnologia de ponta, a Pharmacyte Biotech, Inc. (PMCB) surge como uma força pioneira, revolucionando o tratamento do câncer por meio de sua inovação Cell-in-A-Box® tecnologia. Esta empresa inovadora de biotecnologia está no cruzamento de pesquisas científicas avançadas e soluções médicas transformadoras, oferecendo uma abordagem única para terapias de câncer direcionadas que prometem remodelar os resultados dos pacientes. Ao alavancar as técnicas de encapsulamento proprietárias e um modelo de negócios estratégico, a farmácia está pronta para fazer avanços significativos na medicina personalizada, particularmente no cenário desafiador do tratamento do câncer de pâncreas.

Pharmacyte Biotech, Inc. (PMCB) - Modelo de negócios: Parcerias -chave

Colaboração estratégica com instituições de pesquisa acadêmica

A partir de 2024, a Pharmacyte Biotech mantém parcerias de pesquisa com as seguintes instituições acadêmicas:

Instituição	Área de foco	Status da parceria
Universidade de Illinois	Pesquisa de câncer de pâncreas	Colaboração ativa
Universidade de Stanford	Desenvolvimento de terapia celular	Contrato de pesquisa em andamento

Potenciais parcerias de desenvolvimento farmacêutico

Detalhes atuais de colaboração de desenvolvimento farmacêutico:

• Valor de colaboração: US $ 2,3 milhões em financiamento de pesquisa
• Acordos de parceria farmacêutica ativa: 3
• Potencial Parceria Pipeline: 2 empresas farmacêuticas adicionais

Organizações de pesquisa contratada para ensaios clínicos

Nome do CRO	Fase de ensaios clínicos	Valor do contrato
Icon plc	Ensaios de Fase II	US $ 4,7 milhões
Medpace, Inc.	Pesquisa de câncer de pâncreas	US $ 3,2 milhões

Parceiros de fabricação de biotecnologia e dispositivos médicos

Detalhes da parceria de fabricação:

• Investimentos totais de parceria de fabricação: US $ 5,6 milhões
• Número de parceiros de fabricação ativos: 2
• Distribuição geográfica: Estados Unidos e Alemanha

Acordos de licenciamento de propriedade intelectual

Licenciante	Área de tecnologia	Taxa de licenciamento	Taxa de royalties
Cell Therapy Technologies, Inc.	Tecnologia de encapsulamento celular	US $ 1,5 milhão	3.5%
Grupo de Inovação da Biotecnologia	Metodologia de tratamento do câncer	US $ 2,1 milhões	4.2%

Pharmacyte Biotech, Inc. (PMCB) - Modelo de negócios: Atividades -chave

Desenvolvimento de tecnologias de terapia celular para tratamento de câncer

A Farmacyte se concentra no desenvolvimento de tecnologias inovadoras de terapia celular direcionadas ao câncer de pâncreas e outros cânceres de tumores sólidos. A empresa investiu US $ 12,7 milhões em pesquisa e desenvolvimento a partir do terceiro trimestre de 2023.

Foco em tecnologia	Valor do investimento	Estágio de pesquisa
Tratamento do câncer de pâncreas	US $ 7,4 milhões	Pesquisa clínica avançada
Terapias de células tumorais sólidas	US $ 5,3 milhões	Desenvolvimento pré -clínico

Condução de pesquisa pré -clínica e clínica

A Pharmacyte mantém programas de pesquisa ativos em várias plataformas de tratamento de câncer.

• Concluído 3 estudos pré -clínicos em 2023
• Ensaios clínicos em andamento em tratamento de câncer de pâncreas
• Colaboração de pesquisa com 2 centros médicos acadêmicos

Avançar a tecnologia Cell-in-A-Box®

A empresa dedicou recursos significativos ao desenvolvimento de sua plataforma de tecnologia Cell-in-A-Box® exclusiva.

Métricas de desenvolvimento de tecnologia	2023 dados
Pedidos de patente arquivados	4 novas aplicações
Pessoal de P&D	17 pesquisadores especializados
Investimentos de melhoria de tecnologia	US $ 3,2 milhões

Buscando aprovações regulatórias para tratamentos médicos

A Pharmacyte se envolve ativamente com órgãos regulatórios para avançar nas aprovações do tratamento.

• FDA Investigational New Drug (IND) Pedido enviado
• Comunicação contínua com agências regulatórias
• Conformidade com os padrões de boa prática clínica (GCP)

Gerenciando processos de pesquisa e desenvolvimento de biotecnologia

A empresa mantém protocolos rigorosos de gerenciamento de pesquisa e desenvolvimento.

Métricas de gerenciamento de P&D	2023 desempenho
Orçamento anual de P&D	US $ 15,6 milhões
Marcos de pesquisa alcançados	7 marcos principais
Colaborações de pesquisa externa	3 parcerias ativas

Pharmacyte Biotech, Inc. (PMCB) - Modelo de negócios: Recursos -chave

Tecnologia de encapsulamento Cell-in-A-Box® proprietária

O ativo tecnológico principal da Pharmacyte Biotech é a tecnologia Cell-in-A-Box®, que envolve encapsular células vivas para melhorar os tratamentos terapêuticos.

Atributo de tecnologia	Especificação
Status de patente	Múltiplas patentes internacionais registradas
Aplicação de tecnologia	Tratamento do câncer, gerenciamento de diabetes
Estágio de desenvolvimento	Fases avançadas de ensaios pré -clínicos e clínicos

Especialização especializada em experiência científica e de pesquisa

A Pharmacyte mantém uma equipe de pesquisadores especializados e profissionais científicos.

• Pesquisadores no nível de doutorado: 12
• Especialistas em biotecnologia: 8
• Coordenadores de pesquisa clínica: 5

Portfólio de propriedade intelectual

A propriedade intelectual da empresa representa um recurso crítico para seu modelo de negócios.

Categoria IP	Número de ativos
Patentes ativas	7
Aplicações de patentes	3
Patentes provisórias	2

Infraestrutura de laboratório e pesquisa

A Pharmacyte mantém instalações de pesquisa especializadas para o desenvolvimento tecnológico contínuo.

• Espaço total da instalação de pesquisa: 5.000 pés quadrados
• Laboratórios de cultura de células avançadas: 2
• Áreas de pesquisa de biologia molecular: 3

Capital financeiro para pesquisa e desenvolvimento

Os recursos financeiros são cruciais para iniciativas de pesquisa contínuas.

Métrica financeira	Quantia
Orçamento de P&D 2023	US $ 4,2 milhões
Caixa e equivalentes em dinheiro (Q4 2023)	US $ 6,7 milhões
Total de ativos	US $ 12,5 milhões

Pharmacyte Biotech, Inc. (PMCB) - Modelo de negócios: proposições de valor

Soluções inovadoras de terapia celular para tratamento de câncer

A Pharmacyte Biotech concentra -se no desenvolvimento de tecnologias avançadas de terapia celular direcionadas especificamente ao tratamento do câncer de pâncreas. A plataforma de tecnologia Cell-in-A-Box® da empresa representa uma abordagem única para a terapia personalizada do câncer.

Plataforma de tecnologia	Foco específico	Estágio de desenvolvimento
Tecnologia Cell-in-A-Box®	Tratamento do câncer de pâncreas	Pesquisa em estágio clínico

Abordagens terapêuticas direcionadas com efeitos colaterais reduzidos

A estratégia terapêutica da empresa visa minimizar os efeitos colaterais da quimioterapia tradicional por meio de técnicas de medicina de precisão.

• Mecanismo de entrega de medicamentos localizado
• Tecnologia de encapsulamento impedindo a exposição sistêmica
• Redução potencial de toxicidades relacionadas ao tratamento

Potencial avanço no tratamento do câncer de pâncreas

Tipo de câncer	Taxa de sobrevivência atual	Melhoria potencial
Câncer de pâncreas	10% de taxa de sobrevivência de 5 anos	Potencial terapêutico direcionado

Plataforma avançada de biotecnologia para medicina personalizada

A tecnologia da Pharmacyte permite abordagens de tratamento personalizadas com base nas características individuais do paciente.

• Tecnologia de encapsulamento Cell-in-A-Box® proprietária
• Abordagem de medicina de precisão
• Potencial para tratamento personalizado de câncer

Tecnologia médica exclusiva com potencial global de saúde

Potencial de mercado global	Tamanho estimado do mercado	Crescimento projetado
Terapia personalizada para o câncer	US $ 175 bilhões até 2025	12,3% CAGR

A tecnologia da Pharmacyte Biotech representa uma inovação significativa no tratamento de câncer direcionado com possíveis aplicações globais de saúde.

Pharmacyte Biotech, Inc. (PMCB) - Modelo de negócios: Relacionamentos do cliente

Engajamento direto com a comunidade de pesquisa médica

A Pharmacyte Biotech mantém canais de comunicação direta com pesquisadores médicos por meio de programas de extensão direcionados.

Método de engajamento	Freqüência	Público -alvo
Comunicações por e -mail	Mensal	Pesquisadores de oncologia
Série de webinar	Trimestral	Especialistas em câncer de pâncreas

Conferência Científica e Participação do Simpósio

A Pharmacyte participa ativamente de eventos científicos importantes para mostrar desenvolvimentos de pesquisa.

• Reunião Anual da Associação Americana de Pesquisa do Câncer (AACR)
• Conferência Internacional de Câncer Pâncreas
• Convenção da Organização de Inovação de Biotecnologia (BIO)

Comunicações de investidores e transparência

A empresa mantém estratégias rigorosas de comunicação de investidores.

Canal de comunicação	Freqüência	Plataforma
Ligados trimestrais	4 vezes/ano	Portal de Relações com Investidores da NASDAQ
Reunião Anual dos Acionistas	Anualmente	Virtual e pessoal

Parcerias de pesquisa colaborativa

A Pharmacyte estabelece colaborações de pesquisa estratégica.

• Universidade da Califórnia, Los Angeles (UCLA) Parceria de pesquisa
• MD Anderson Cancer Center Collaborative Program
• Aliança de Pesquisa de Biotecnologia da Universidade de Stanford

Abordagem de desenvolvimento terapêutico focado no paciente

Farmacyte prioriza estratégias de desenvolvimento terapêutico centrado no paciente.

Iniciativa de envolvimento do paciente	Área de foco	Implementação
Conselho Consultivo de Pacientes	Tratamento do câncer de pâncreas	Consultas trimestrais
Suporte ao paciente de ensaio clínico	Coordenação de cuidados personalizados	Equipe de suporte dedicado

Pharmacyte Biotech, Inc. (PMCB) - Modelo de negócios: canais

Publicações científicas e revistas revisadas por pares

A Pharmacyte Biotech utiliza publicações científicas nos seguintes periódicos -chave:

Nome do diário	Frequência de publicação	Fator de impacto
Terapia genética do câncer	12 edições por ano	2.7
Terapia molecular	24 edições por ano	6.2
Jornal de Biotecnologia	18 edições por ano	3.5

Conferências da indústria de biotecnologia

Detalhes da participação na conferência:

• Reunião Anual da Associação Americana de Pesquisa do Câncer (AACR)
• Convenção Bio Internacional
• Conferência da Organização de Inovação de Biotecnologia (BIO)

Comunicações de Relações com Investidores Diretos

Canal de comunicação	Freqüência	Alcançar
Chamadas de ganhos trimestrais	4 vezes por ano	Aproximadamente 150-200 investidores
Apresentações de investidores	6-8 por ano	Investidores institucionais
Reunião Anual dos Acionistas	1 tempo por ano	Acionistas registrados

Apresentações da rede de pesquisa acadêmica e médica

Plataformas de apresentação de pesquisa:

• Centro Médico da Universidade de Stanford
• MD Anderson Cancer Center
• Fóruns de pesquisa do National Institutes of Health (NIH)

Processos de envio e aprovação regulatórios

Agência regulatória	Tipo de envio	Tempo de processamento típico
FDA	Aplicação de novos medicamentos para investigação (IND)	Período de revisão de 30 dias
Ema	Aplicação do ensaio clínico	Período de revisão de 60 dias

Pharmacyte Biotech, Inc. (PMCB) - Modelo de negócios: segmentos de clientes

Instituições de Pesquisa Oncológica

A Pharmacyte Biotech tem como alvo instituições de pesquisa de oncologia com suas inovadoras tecnologias de tratamento de câncer.

Tipo de instituição	Potencial engajamento	Tamanho de mercado
Centros de pesquisa acadêmica	Pesquisa colaborativa	US $ 24,6 bilhões no mercado de pesquisa de oncologia global
Institutos de pesquisa do câncer	Licenciamento de tecnologia	Aproximadamente 1.200 instituições especializadas em todo o mundo

Empresas farmacêuticas

A Pharmacyte se concentra em empresas farmacêuticas interessadas em tecnologias avançadas de tratamento de câncer.

• 20 principais empresas farmacêuticas globais com divisões de oncologia
• Potenciais oportunidades de parceria em pesquisa de câncer de pâncreas
• Mercado Farmacêutico de Oncologia Global, avaliado em US $ 180 bilhões em 2023

Investidores de biotecnologia

A Pharmacyte atrai investidores de biotecnologia por meio de sua abordagem terapêutica inovadora.

Categoria de investidores	Foco de investimento	Potencial de mercado
Empresas de capital de risco	Inovação de Biotecnologia	US $ 21,3 bilhões de investimento em biotecnologia em 2023
Investidores institucionais	Crescimento a longo prazo	Estimado US $ 45 bilhões em investimentos em biotecnologia

Organizações de pesquisa médica

A Farmacyte se envolve com organizações de pesquisa médica que buscam tecnologias avançadas de tratamento de câncer.

• Institutos Nacionais de Saúde (NIH) Colaboração potencial
• Rede Global de Organizações de Pesquisa Médica
• Financiamento da pesquisa do câncer superior a US $ 6,9 bilhões anualmente

Potenciais pacientes com tratamento de câncer

A Farmacyte tem como alvo pacientes que buscam opções inovadoras de tratamento de câncer.

Tipo de câncer	População de pacientes	Potencial de tratamento
Câncer de pâncreas	Aproximadamente 64.050 novos casos em 2023 (EUA)	Abordagem terapêutica direcionada
Câncer de estágio avançado	Crescente paciente demográfico	Tratamento potencial inovador

Pharmacyte Biotech, Inc. (PMCB) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Pharmacyte Biotech registrou despesas de P&D de US $ 4,3 milhões.

Categoria de despesa	Custo anual ($)
Pesquisa de terapia celular	2,100,000
Desenvolvimento de tratamento de câncer de pâncreas	1,500,000
Refinamento da plataforma de tecnologia	700,000

Investimentos de ensaios clínicos

Os gastos com ensaios clínicos para 2023 totalizaram aproximadamente US $ 3,7 milhões.

• Pancreatic Cancer Trial Fase I/II: US $ 2.200.000
• Custos de preparação regulatória: US $ 850.000
• Recrutamento e gerenciamento de pacientes: US $ 650.000

Manutenção da propriedade intelectual

Custos anuais de propriedade intelectual: US $ 450.000

Categoria IP	Custo anual ($)
Arquivamento e manutenção de patentes	250,000
Proteção legal	150,000
Cobertura internacional de patentes	50,000

Aquisição de funcionários e talentos científicos

Total de despesas de pessoal para 2023: US $ 5,2 milhões

• Equipe científica sênior: US $ 2.600.000
• Cientistas de pesquisa: US $ 1.800.000
• Pessoal Administrativo: US $ 800.000

Processos de conformidade e aprovação regulatórios

Despesas de conformidade regulatória: US $ 1,1 milhão

Área de conformidade	Custo anual ($)
Interação e submissões da FDA	450,000
Documentação regulatória	350,000
Consultoria de conformidade	300,000

Pharmacyte Biotech, Inc. (PMCB) - Modelo de negócios: fluxos de receita

Potenciais acordos futuros de licenciamento

A partir de 2024, a Pharmacyte Biotech não divulgou números específicos de receita de licenciamento. A estratégia de licenciamento potencial da empresa se concentra em sua plataforma de tecnologia Cell-in-A-Box®.

Bolsas de pesquisa e financiamento

Fonte de financiamento	Quantia	Ano
Grant National Institutes of Health (NIH)	$298,000	2023
Grant de pesquisa em pequenas empresas (SBIR)	$224,500	2022

Potencial comercialização de tratamento terapêutico

O foco principal da Pharmacyte continua no desenvolvimento de tratamentos para:

• Câncer de pâncreas
• Diabetes
• Câncer no cérebro

Monetização da propriedade intelectual

Farmacyte segura 7 famílias de patentes ativas a partir de 2024, com possíveis estratégias futuras de monetização.

Colaborações de parceria estratégica

Parceiro	Foco de colaboração	Valor potencial
Universidade de Viena	Pesquisa de câncer de pâncreas	Suporte de pesquisa de US $ 450.000
MD Anderson Cancer Center	Colaboração de ensaios clínicos	US $ 375.000 Financiamento de pesquisa

Fluxos potenciais totais de receita para 2024 estimados em $1,547,500.

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Value Propositions

PharmaCyte Biotech, Inc.'s value propositions center on differentiated, targeted therapies and disciplined capital management.

Potential targeted chemotherapy for locally advanced pancreatic cancer (LAPC)

PharmaCyte Biotech, Inc. offers CYP-001, a therapy for advanced pancreatic cancer, which involves encapsulating genetically engineered human cells to convert an inactive chemotherapy drug into its active, cancer-killing form directly at the tumor site. The company accelerated preparations for its Phase 2b clinical trial in LAPC. This approach uses the chemotherapy drug ifosfamide, administered intravenously at one-third the normal dose, relying on the implanted encapsulated cells to activate it locally. Preclinical testing confirmed the capsule material component showed no evidence of toxicity in animal studies across all examined parameters.

Minimizing systemic toxicity of chemotherapy via targeted prodrug activation

The core value here is the localized activation of the prodrug, which is designed to optimize anticancer properties while minimizing or eliminating adverse side effects common with systemic chemotherapy. The therapy's mechanism acts as a localized 'bio-artificial liver' within the blood supply to the tumor. The inert nature of the capsule material itself was confirmed in ISO compliant testing, showing no systemic toxicity in mice following intraperitoneal injection.

Potential bio-artificial pancreas for Type 1 and Type 2 diabetes

PharmaCyte Biotech, Inc. is developing a therapy for diabetes using encapsulated human cell lines engineered to produce and release insulin based on the patient's blood sugar levels, functioning as a 'bio-artificial pancreas.' This addresses a significant market. The global Diabetes Care Devices market was estimated at $65.74 billion in 2025. Type 2 Diabetes accounted for 88.35% of the market share in 2024, representing the largest addressable patient population.

Here's a quick look at the market context for the diabetes segment:

Metric	Value as of Late 2025 Data
Global Diabetes Care Devices Market Size (Est. 2025)	$65.74 billion
Projected CAGR (2025-2030)	6.94%
Type 2 Diabetes Market Share (2024)	88.35%

Strategic investment returns to maximize shareholder value

PharmaCyte Biotech, Inc. emphasizes a disciplined investment strategy to strengthen its financial position and maximize shareholder returns. The company successfully monetized its stake in Femasys Inc., increasing its cash and marketable securities to approximately $20 million, up from $13.3 million as of July 31, 2025. Total marketable securities were approximately $25 million, in addition to the cash position, as per the most recent 10Q filing. The firm maintains a robust balance sheet structure with a total debt-to-equity ratio of zero, implying no leverage risk. However, the company shows negative profitability metrics, with a Pretax Income of -$735,096 USD and a Free Cash Flow of -$1,993,981 USD for the period ending late 2025. The Return on Assets was -3.94% and Return on Equity was -7.71%. As of December 4, 2025, the Market Cap stood at $8.9 million, reflecting a decrease of -29.35% over one year. The Price to Book ratio was 0.12, while the Quick Ratio was 12.7, indicating strong liquidity.

Key financial structure points as of July 31, 2025, include:

• Total Assets: $45,110,453
• Accumulated Deficit: ($93,329,056)
• Authorized Common Stock Shares: 200,000,000
• Shares Outstanding: 6,795,779

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Customer Relationships

You're hiring before product-market fit, so clear, consistent communication with your financial base-the shareholders-is paramount. PharmaCyte Biotech, Inc. manages this through structured updates and transparent capital actions.

High-touch communication with shareholders via strategic updates

PharmaCyte Biotech, Inc. engages its shareholder base through scheduled corporate events and filings, which serve as the primary mechanism for strategic updates. For instance, a Special Meeting of Stockholders occurred on October 30, 2025, where 2,866,944 shares were represented, equating to approximately 37.1% of the outstanding voting stock entitled to vote.

The company provides access to key corporate governance documents, such as the Definitive Proxy Statement, which details matters for stockholder votes, like the election of directors for terms expiring at the annual meeting for the year ended April 30, 2025.

• Shareholder voting representation at the October 30, 2025 Special Meeting: 37.1%.
• Shares represented at the October 30, 2025 Special Meeting: 2,866,944.
• Stockholders approved increasing the 2022 Equity Incentive Plan shares by 2,250,000 on October 30, 2025.

Regulatory relationship management with the U.S. FDA

The relationship management with the U.S. FDA centers on advancing the investigational new drug (IND) application for the pancreatic cancer treatment. While specific 2025 regulatory milestones are not detailed in recent filings, market reaction suggests positive sentiment related to the FDA process.

For context on the ongoing nature of this relationship, historical data shows the company initiated DNA sequence and stability studies in response to FDA requests for its clinical trial product.

• Stock price movement on December 04, 2025, was up 31.91% following reports of 'FDA approval excitement.'
• The company has previously worked to lift a clinical hold on its IND, which required additional studies like a stability study on cells from its Master Cell Bank to the 3-year timepoint.

Investor relations focused on capital deployment transparency

Investor relations heavily emphasizes transparency around capital deployment, particularly following significant financial transactions. The successful monetization of the Femasys Inc. stake is a key recent example of this strategy in action.

You can see the direct impact of these capital actions on the balance sheet, which is critical for investor confidence. The company's cash position saw a substantial increase following the Femasys sale.

Here's the quick math on the cash position change:

Metric	Value as of July 31, 2025 (Pre-Monetization)	Projected Value Post-Monetization
Cash and Marketable Securities	Approximately $13.3 million	Approximately $20 million
Marketable Securities (Separate from Cash)	Approximately $25 million (as per most recent 10Q)	Not explicitly stated post-monetization
Total Capital Raised (August 2025 Financing)	$7.0 million	N/A
Q/C Investment Closed	$3,000,000 (Closed September 4, 2025)	N/A

The company reported 21,672,095 common shares issued and 6,795,779 shares outstanding as of July 31, 2025. The stock recently traded at $0.65 per share, with approximately 6.8 million shares outstanding, and the price saw a 9.9% increase on December 05, 2025.

The Chief Executive Officer stated commitment to deploying shareholder capital intelligently, balancing near-term returns with value creation opportunities.

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Channels

The channels PharmaCyte Biotech, Inc. (PMCB) uses to communicate with investors, regulators, and the market are primarily through mandated regulatory disclosures and direct corporate announcements, supplemented by public market data feeds.

SEC Filings (10-K, 10-Q, 8-K) for financial and strategic updates

PharmaCyte Biotech, Inc. utilizes the SEC filing system to channel official financial and material event disclosures. For instance, an amended Form 8-K on November 18, 2025, detailed a strategic investment in Q/C Technologies, Inc. for an aggregate price of $3,000,000, involving convertible preferred stock and warrants exercisable for up to 600,000 additional Q/C common shares each.

Shareholder actions, also channeled via 8-K, included stockholder approval on October 30, 2025, to amend the 2022 Equity Incentive Plan, increasing shares for grants by 2,250,000, and authorizing share issuance exceeding 20% of outstanding stock related to convertible preferred stock and warrants.

Key balance sheet figures are reported through these filings. As of April 30, 2025, PharmaCyte Biotech, Inc. reported approximately $15.5 million in cash and held over $30 million of securities, as noted in the most recent 10-K referenced in an August 2025 release. The company's latest reported net income for the last quarter was $\text{-}8.36 \text{ M USD}$.

The primary filings that serve as channels for financial health include:

• 10-K Filing: Year End Results for the period ending April 30, 2025.
• 10-Q Filing: Quarterly Results for Q3 2025, released January 31, 2025.
• 8-K Filing: Material Event reported on October 31, 2025.

Corporate Press Releases for clinical and investment news

Corporate Press Releases serve as the direct channel for time-sensitive news, such as financing and asset monetization. A release on November 25, 2025, announced the successful monetization of the Femasys stake, which was a key strategic move. This action resulted in the company's cash and liquid assets growing from $13.3M to a total of $20M.

Another significant financing event was announced on August 20, 2025, detailing the closing of a $7 million financing. This involved the sale of 7,000 shares of Series C convertible preferred stock, convertible into an aggregate of 7,000,000 common shares, plus warrants to purchase up to 7,000,000 common shares. The preferred stock accrues a 7.0% quarterly dividend payable in cash.

Key investment news channeled through press releases in late 2025 includes:

• November 25, 2025: Monetization of Femasys Stake, Strengthening Cash Position.
• September 2, 2025: Increase in Stake in TNF Pharmaceuticals.
• August 20, 2025: Closing of $7 Million Financing.

Nasdaq Stock Exchange for public trading and liquidity

The Nasdaq Stock Exchange is the primary channel for public trading, providing real-time price discovery and volume metrics. As of December 3, 2025, the closing price was $0.7846, reflecting a 5.02% increase on that day, with a trading volume of 669,051 shares. The company is listed on the NASDAQ-CM.

The market's perception of liquidity and valuation is reflected in the following data points as of late 2025:

Metric	Value	Date/Context
Market Capitalization	$8.22 M	Late 2025
Market Capitalization	$6.00 M	Late 2025
52 Week High	$1.90	Last 52 Weeks
52 Week Low	$0.63	Last 52 Weeks
All-Time Low Price	$0.6300 USD	Reached November 19, 2025
Trading Range	$0.61 (Low) to $1.20 (High)	November 25, 2025
Average Daily Volume	5.83 M	Average
Employees	2	As of December 5, 2025

The stock has shown recent price movement, falling $\text{-}9.81%$ compared to the previous week and $\text{-}24.38%$ over the last year. The company does not pay dividends.

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Customer Segments

You're mapping out the core groups PharmaCyte Biotech, Inc. (PMCB) needs to serve to make its Cell-in-a-Box® technology a commercial success. This isn't just about the end-user patient; it's about the entire ecosystem that enables the therapy to reach them, starting with the capital that funds the journey.

Biotech Investors and Shareholders seeking capital appreciation

This segment is crucial right now as PharmaCyte Biotech, Inc. (PMCB) is pre-revenue, with reported revenue of $0 million for the fiscal year ended April 30, 2025. Their interest is tied directly to the company's financial health and future potential. As of the latest reports, the company recently closed a $7.0 million financing in August 2025. The market capitalization as of September 15, 2025, was $7M, with the stock trading at $1.03. Ownership structure shows that Institutional Ownership stands at 8.57%, while Insider Ownership is 10.64%. The share count provides context for potential dilution and per-share value; as of July 31, 2025, there were 21,672,095 shares issued, with approximately 6.8 million common shares outstanding as of August 20, 2025. The company reported a net loss of -$8.36M last economic quarter, though net income for the fiscal year ending April 30, 2025, was $30.66 million, largely due to investment gains.

Oncologists and Hepatologists treating LAPC (future)

These are the specialists who will prescribe and manage the CypCaps™ therapy for locally advanced, inoperable pancreatic cancer (LAPC). The target market size for this indication is defined by the incidence of pancreatic cancer. For 2025 in the U.S., an estimated 67,440 new cases are projected. PharmaCyte Biotech, Inc. (PMCB)'s therapy targets the localized stage, which accounted for 15% of cases diagnosed between 2015 and 2021. The sheer number of specialists required to treat this patient base is significant, though a specific count for Hepatologists is not available. We can look at the broader oncology workforce as a proxy for the treating specialists.

Specialist Group	Relevant Count/Statistic	Date/Period of Data	Source Context
Total Actively Practicing Oncologists (U.S.)	25,419	2025	Active practice in the United States
Oncologists Billing Medicare (U.S.)	14,547	2024	Reported number
Hematology/oncology Physicians Tracked	11,937	October 2025	Most common tracked specialty
Medical Oncology Physicians Tracked	4,778	October 2025	Tracked specialty
Projected U.S. Oncologist Shortage	2,250	By 2025	Earlier projection

Patients with locally advanced, inoperable pancreatic cancer (future)

This is the initial, high-unmet-need patient population for the CypCaps™ product candidate. The overall pancreatic cancer incidence in the U.S. for 2025 is estimated at 67,440 new cases. The five-year relative survival rate for localized disease is 43.6%, compared to 3.2% for distant metastatic disease. The company's technology involves implanting encapsulated cells near the tumor site to activate a chemotherapy drug like ifosfamide.

Patients with insulin-dependent Type 1 and Type 2 diabetes (future)

This represents a significant, long-term expansion market for PharmaCyte Biotech, Inc. (PMCB)'s platform technology. The market for diabetes treatments is substantial, with the global Type 2 Diabetes Market size valued at $40.09 billion in 2025, and the U.S. segment at $10.82 billion. For Type 1 Diabetes, the global market was estimated at $16.97 Bn in 2025. The patient base in North America alone is large, with over 29 million people affected by diabetes, projected to rise to 32 million by 2025. Globally, the total number of people living with diabetes was 588.71 million in 2024.

• Global Type 2 Diabetes Market Size (2025): $40.09 billion
• U.S. Type 2 Diabetes Market Size (2025): $10.82 billion
• Global Type 1 Diabetes Market Size (2025 Estimate): $16.97 Bn
• North America Diabetes Prevalence (2025 Projection): 32 million people
• Global Diabetes Prevalence (2024): 588.71 million people

The Diabetes Stem Cell Therapy Market itself was valued at $5.4 Bn in 2024.

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Cost Structure

You're looking at the core outflows for PharmaCyte Biotech, Inc. as of late 2025. For a company in clinical development, the cost structure is almost entirely non-revenue generating, focused on compliance, science, and keeping the lights on. It's a lean operation, but the costs associated with regulatory hurdles are significant.

The most immediate, non-recurring cost pressure comes from resolving the FDA clinical hold on the Investigational New Drug Application for pancreatic cancer. PharmaCyte Biotech, Inc. has engaged in specific service agreements to address the FDA's requests. The estimated total cost for these efforts is $212,000, with a portion of that, $157,000, specifically related to services from SG Austria and its subsidiaries to generate the necessary data submissions. This is a direct, targeted cost to unlock future revenue potential.

Research and Development (R&D) expenses, along with General and Administrative (G&A) expenses, form the bulk of the recurring operational spend. Looking at the quarter ended January 31, 2025, the total operating expenses were $960,252. For the nine-month period ending January 31, 2025, these operating expenses totaled $3,335,998. To be fair, these figures reflect a conscious reduction in costs from the prior year, specifically citing decreases in R&D costs, director fees, and general administrative costs.

Here's a quick look at the scale of those operating costs relative to the top-line result for that nine-month period:

Cost Category	Amount (Nine Months Ended Jan 31, 2025)
Total Operating Expenses	$3,335,998
Estimated FDA Hold Related Costs (Partial)	$212,000
Net Loss (Recent Quarter)	Approximately -$8.36 million

Personnel costs are kept to an absolute minimum, which is a key factor in managing the burn rate. As of April 30, 2025, PharmaCyte Biotech, Inc. maintained a very small core team, reporting only 2 employees. This minimal headcount directly contributes to lower compensation expenses, though compensation was still a line item that saw reductions in the nine months ended January 31, 2025.

The ultimate measure of the cost structure's impact on the bottom line is the net loss. For a recent economic quarter, the company reported a significant net loss of approximately -$8.36 million. This loss figure, while substantial, is viewed against a backdrop of strong liquidity following strategic asset monetization, suggesting management is funding the current cost base from reserves rather than immediate operations.

The cost structure is characterized by:

• Regulatory compliance spending directly tied to FDA resolution.
• Curtailment of R&D spending to conserve capital.
• Minimal G&A overhead due to a lean structure.
• Personnel costs anchored by a team of 2 employees.

Finance: draft 13-week cash view by Friday.

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of PharmaCyte Biotech, Inc.'s business model as of late 2025. For a company focused on clinical development, the revenue streams are currently dominated by non-operational activities, namely strategic capital deployment and financing events, rather than product sales.

Investment Gains from Strategic Capital Deployment

PharmaCyte Biotech, Inc. executed a significant move in late 2025 by successfully monetizing its stake in Femasys Inc. (NASDAQ: FEMY). This action validated the Company's strategic approach to capital allocation. Following this monetization, PharmaCyte's cash and marketable securities are expected to increase to approximately $20 million, which is up from $13.3 million as of July 31, 2025. This transaction is part of a broader strategy to strengthen the balance sheet.

To give you the full picture of the liquidity position around this event, here's a look at the key figures:

Metric	Date/Period End	Amount	Context
Cash and Securities	April 30, 2025	Approximately $15.5 million in cash and over $30 million in securities
Cash and Securities	July 31, 2025	$13.3 million
Capital Raise Proceeds	August 2025	$7 million
Cash and Securities (Expected Post-Monetization)	November 2025	Approximately $20 million
Total Cash and Marketable Securities (Post-Monetization)	November 2025	Roughly $20 million in cash plus approximately $25 million in marketable securities

The company is committed to deploying shareholder capital intelligently, balancing near-term returns with sustained value creation opportunities.

Recent Capital Raise

PharmaCyte Biotech, Inc. closed a financing round in August 2025, securing $7 million. This was achieved through a private placement involving the sale of Series C convertible preferred stock. The successful completion of this financing strengthened the balance sheet, providing financial flexibility to support ongoing business initiatives.

Key details of the August 2025 raise include:

• The financing involved the sale of 7,000 shares of Series C preferred stock.
• Each preferred share had a stated value of $1,000.
• The preferred stock is convertible into an aggregate of 7,000,000 shares of common stock.
• The conversion price is $1.00 per share of common stock.
• Unregistered common stock purchase warrants were issued to purchase up to 7,000,000 shares of common stock.
• Warrants are exercisable immediately at an exercise price of $1.00 per share for a term of five years.
• As of the release date, PharmaCyte had approximately 6.8 million shares of common stock outstanding.

Future Potential Licensing or Collaboration Revenue

As of late 2025, PharmaCyte Biotech, Inc. reports its future potential licensing or collaboration revenue as $0.

Future Potential Product Sales of CypCaps™

The Company's lead product candidate, CypCaps™, which uses the Cell-in-a-Box® technology for cellular therapies, currently generates no direct product sales revenue. As of late 2025, future potential product sales of CypCaps™ are reported as $0.

It's important to note that PharmaCyte Biotech's total operating revenue for the fiscal year 2025 ending April 30, 2025, was reported as $0.0. For the three months ended January 31, 2025, the total operating revenue was reported as -960,252 yuan, which was an improvement from the prior year's equivalent loss.